A €9 Billion Dividend Fund Sits 0.77% From Its Peak With a September Payout on the Horizon

VanEck Developed Markets Dividend Leaders ETF closes at €55.23, 0.77% from record, with 2.98% yield and 10-year payout streak.

The VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF closed the week at €55.23, leaving it just 0.77 percent shy of the all-time high of €55.66 it set on August 4. For income-focused investors, the more pressing date on the calendar is September, when the fund's next quarterly distribution falls due.

The Amsterdam-listed fund has delivered a 14.97 percent gain since the start of the year, with the 12-month return stretching to 27 percent. Anyone who bought at the trough a year ago is sitting on a gain of more than 28 percent. Yet the advance has been measured rather than frenetic — the 30-day annualized volatility of 9.23 percent underscores the moderate swings typical of a dividend strategy.

A Payout Record That Speaks for Itself

The fund has now distributed without interruption for ten consecutive years. The most recent payment of €0.81 per share landed on June 10, 2026, with the entitlement date set three days earlier on June 3. Distributions follow a quarterly rhythm — March, June, September and December — which puts the next payout firmly in September.

Over the trailing twelve months, distributions have totaled €1.65 per share, and the same figure is projected for the coming year. That translates into a dividend yield of 2.98 percent at current prices.

Heavyweights Dominate the Portfolio

The fund tracks the Morningstar Developed Markets Large Cap Dividend Leaders Screened Select Index, holding 110 positions — 100 equities and no bonds. The selection methodology prioritizes payout continuity and sustainability over raw yield, an approach designed to sidestep the classic dividend trap where a high payout ratio masks a fragile earnings base.

The sector mix follows the familiar contours of high-dividend strategies: financials, healthcare and energy lead the way, while growth technology barely registers. The ten largest positions — HSBC Holdings, Verizon Communications, Nestlé, Pfizer, Shell, TotalEnergies, PepsiCo, Allianz, Intesa Sanpaolo and Novo Nordisk — together account for 34.30 percent of the fund's assets.

The fund's €9.1 billion in assets under management are replicated physically, meaning it buys every index constituent directly. The total expense ratio stands at 0.38 percent, and the fund has been running since May 2016.

Technicals Point to a Constructive Setup

The chart tells a story of sustained momentum. The fund trades 8.76 percent above its 200-day moving average of €50.78, with shorter-term averages also trailing the price — a configuration that typically signals an intact uptrend. The relative strength index of 64.3 suggests meaningful buying pressure that has not yet tipped into overbought territory.

The path ahead hinges on the heavyweight holdings. Energy names like Shell and TotalEnergies, along with financials such as HSBC and Allianz, have historically shown sensitivity to interest-rate expectations and currency moves — two forces that have repeatedly shaped the fund's short-term swings. With the record high a mere 0.77 percent away, a decisive break above €55.66 would open fresh ground, while the September distribution gives patient holders another reason to stay the course.